Gilead Sciences Quarterly Cash Flow Statement
NASDAQ: GILDHealth CareBiotechnology: Biological Products (No Diagnostic Substances)USD
At close: Oct 9, 4:00 PM ET · Delayed 15 min
Gilead Sciences free cash flow
In the quarter ended Jun 30, 2026, Gilead Sciences generated $3.57 billion of operating cash flow and spent $140.0 million on capital expenditures. That left free cash flow of $3.43 billion, a free-cash-flow margin of 44.0% of revenue. Free cash flow was up 376.8% from the prior year's $720.0 million.
Gilead Sciences returned $1.38 billion to shareholders: $1.03 billion in dividends and $355.0 million in share repurchases, equal to 40% of free cash flow. Free cash flow covered dividend payments 3.3 times.
Summary generated from market data by MetaCap's automated system. Methodology
Gilead Sciences cash flow statement (quarterly)
| Quarter (USD) | Q2 20262026-06-30 | Q1 20262026-03-31 | Q4 20252025-12-31 | Q3 20252025-09-30 | Q2 20252025-06-30 | Q1 20252025-03-31 | Q4 20242024-12-31 | Q3 20242024-09-30 | Q2 20242024-06-30 | Q1 20242024-03-31 | Q4 20232023-12-31 | Q3 20232023-09-30 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net Income | -10.50B | 2.02B | 2.18B | 3.05B | 1.96B | 1.31B | 1.78B | 1.25B | 1.61B | -4.17B | 1.42B | 2.17B |
| Net Income growth (YoY) | -635.51% | +53.69% | +22.43% | +143.58% | +21.44% | — | +25.83% | -42.31% | +55.34% | -523.35% | -13.23% | +21.61% |
| Depreciation & Amortization | 98.00M | 93.00M | 90.00M | 90.00M | 93.00M | 97.00M | 95.00M | 94.00M | 98.00M | 94.00M | 91.00M | 86.00M |
| Stock-Based Compensation | 231.00M | 218.00M | 230.00M | 230.00M | 225.00M | 209.00M | 222.00M | 216.00M | 210.00M | 187.00M | 201.00M | 202.00M |
| Change in Working Capital | -135.00M | -682.00M | -470.00M | -175.00M | -714.00M | -481.00M | -53.00M | 531.00M | -375.00M | -251.00M | 155.00M | -668.00M |
| Operating Cash Flow | 3.57B | 2.54B | 3.33B | 4.11B | 827.00M | 1.76B | 2.98B | 4.31B | 1.32B | 2.22B | 2.17B | 1.75B |
| Capital Expenditures | -140.00M | -117.00M | -205.00M | -147.00M | -107.00M | -104.00M | -147.00M | -141.00M | -130.00M | -105.00M | -215.00M | -122.00M |
| Investing Cash Flow | -10.35B | 1.77B | -1.83B | -427.00M | -2.12B | -415.00M | -225.00M | -710.00M | -307.00M | -2.21B | -727.00M | -229.00M |
| Dividends Paid | -1.03B | -1.04B | -994.00M | -1.00B | -994.00M | -1.01B | -973.00M | -983.00M | -972.00M | -990.00M | -943.00M | -953.00M |
| Share Repurchases | -355.00M | -419.00M | -230.00M | -435.00M | -527.00M | -730.00M | -350.00M | -300.00M | -100.00M | -400.00M | -150.00M | -300.00M |
| Debt Issued | — | — | — | — | — | — | 3.46B | — | — | — | 1.00M | — |
| Debt Repaid | -17.00M | -2.77B | -8.00M | -9.00M | -9.00M | -1.76B | -7.00M | -112.00M | -1.85B | 0 | 0 | -2.25B |
| Financing Cash Flow | 2.34B | -4.24B | -1.26B | -1.49B | -1.57B | -3.43B | 2.26B | -1.38B | -2.95B | -1.36B | -1.10B | -1.52B |
| Net Change in Cash | -4.45B | 65.00M | 233.00M | 2.19B | -2.78B | -2.06B | 4.96B | 2.26B | -1.95B | -1.37B | 380.00M | 1.00M |
| Free Cash Flow | 3.43B | 2.43B | 3.12B | 3.96B | 720.00M | 1.65B | 2.83B | 4.17B | 1.20B | 2.11B | 1.95B | 1.63B |
This table shows 12 quarterly periods of Gilead Sciences's cash flow statement, from Q2 2026 back to Q3 2023, across 14 line items including net income, depreciation & amortization, stock-based compensation. Values in USD; B = billions, M = millions. Fiscal periods follow GILD's reporting calendar. What is a cash flow statement?